Skip to content

RoosterBio Logo

Site Navigation

  • Our Technology
    • Foundation for Multiple Therapeutics
    • Powerful Technology
    • Built-In Manufacturing Process
  • Products
    • Human Primary Cells
      • Bone Marrow-derived hMSCs
      • Adipose-derived hMSCs
      • Umbilical Cord-derived hMSCs
      • Neonatal Dermal Fibroblasts
      • QuickShip™ Cell Banks
    • Cell & Exosome Media
      • hMSC Expansion Media
      • hMSC Bioreactor Feed
      • Exosome Media
      • QuickShip™ MSC & Exosome Media
    • cGMP CliniControl™ Products
      • Human Primary Cells
      • hMSC Expansion Media
      • hMSC Bioreactor Feed
      • Exosome Media
      • Genetic Engineering Media
    • Engineered Human Cell Lines
      • hTERT-Modified hMSCs
    • Genetic Engineering Tools
      • Genetic Engineering Media
    • Cell & Media Kits
      • hMSC Starter Kits
      • hMSC Donor & Tissue Screening Kits
      • hMSC & Exosome Bioreactor Kits
    • Human Exosomes / Extracellular Vesicles
      • MSC-Derived Exosomes
      • QuickShip™ Exosomes
      • QuickShip™ Downstream Processing
  • Services
    • Process Development Services
    • hMSC Analytical Services
    • Exosome/Extracellular Vesicle Analytical Services
    • QuickShip™ Solutions
  • Knowledge Center
    • Resources
    • CoAs & QC Briefs
    • Publications
    • Videos & Webinars
    • Blog Articles
  • About Us
    • Why RoosterBio?
    • Our Leadership
    • Our Collaborators
    • Our Culture
    • Careers
    • FAQs
  • News & Events
    • News
    • Events
    • Press Releases
    • Media Kit
  • Contact Us

Publications

Exosome-Based Drug Delivery: a Next-Generation Platform for Cancer, Infection, Neurological and Immunological Diseases, Gene Therapy and Regenerative Medicine

October 2025 Bioprinting, Bioprocessing, Blood, Cancer, Cell Therapy, Clinical, Dermal and Wound, Drug Screening, Exosomes / Extracellular Vesicles, Gene Editing, Immunomodulation, MedTech, Devices, & Materials, Tissue Engineering

miR29a-Loaded Extracellular Vesicles Derived From Human Mesenchymal Stem Cells Inhibit Fibrotic and Inflammatory Signaling

October 2025 Bioprinting, Cell Therapy, Dermal and Wound, Exosomes / Extracellular Vesicles, Immunomodulation, Tissue Engineering

IGF-1 Peptide Mimetic-functionalized Hydrogels Enhance MSC Survival and Immunomodulatory Activity

September 2025 Bioprinting, Bioprocessing, Cardiovascular, Cell Therapy, Dermal and Wound, Diabetes, Immunomodulation, MedTech, Devices, & Materials, Tissue Engineering

Picoliter Ice Particles By Supersonic Cryogenic Jets for Transdermal Drug Delivery: Extracellular Vesicle Application for Skin Diseases

September 2025 Bioprocessing, Cell Therapy, Clinical, Dermal and Wound, Exosomes / Extracellular Vesicles, Immunomodulation

Exogenous Delivery of Sphingomyelinase Mediates Mesenchymal Stromal Cell-Extracellular Vesicle Biogenesis, Alters Cargo Sorting, and Therapeutic Potency in Vitro

August 2025 Bioprocessing, Cell Therapy, Dermal and Wound, Drug Screening, Exosomes / Extracellular Vesicles, Immunomodulation

The PPARβ/δ-induced Mesenchymal Stromal Cell Secretome Has Cytoprotective Effects Via ANGPTL4 in a Pre-Clinical Model of Acute Lung Inflammation

July 2025 Bioprocessing, Cell Therapy, Clinical, Dermal and Wound, Exosomes / Extracellular Vesicles, Immunomodulation, Lung, Orthopedic

Production of GMP-Grade Bone Marrow-Derived Mesenchymal Stromal Cell (BM-MSC) Secretome for Ocular Diseases

May 2025 Bioprocessing, Cell Therapy, Clinical, Dermal and Wound, Exosomes / Extracellular Vesicles, Immunomodulation, Orthopedic

Exosomes in Dermatology: Emerging Roles in Skin Health and Disease

May 2025 Bioprinting, Bioprocessing, Cancer, Cell Therapy, Clinical, Dermal and Wound, Drug Screening, Exosomes / Extracellular Vesicles, Tissue Engineering

The VEGF‐Mediated Cytoprotective Ability of MIF‐Licensed Mesenchymal Stromal Cells in House Dust Mite‐Induced Epithelial Damage

November 2024 Bioprocessing, Cardiovascular, Cell Therapy, Dermal and Wound, Drug Screening, Exosomes / Extracellular Vesicles, Immunomodulation, Lung, Orthopedic

A Bioactive Hydrogel Based on Notochordal Cell-Derived Matrix Stimulates Nucleus Pulposus Regeneration

October 2024 Bioprinting, Bioprocessing, Cell Therapy, Clinical, Dermal and Wound, Exosomes / Extracellular Vesicles, MedTech, Devices, & Materials, Pain, Tissue Engineering
1 2 3 4 5 6 Next

Sidebar Navigation

  • Bioprinting
  • Bioprocessing
  • Blood
  • Cancer
  • Cardiovascular
  • Cell Therapy
  • Clinical
  • Dermal and Wound
  • Diabetes
  • Drug Screening
  • Exosomes / Extracellular Vesicles
  • Gene Editing
  • Genetic
  • Immunomodulation
  • Lung
  • MedTech, Devices, & Materials
  • Orthopedic
  • Pain
  • Pulmonary
  • Renal
  • Tech Segment
  • Therapeutic Indication
  • Tissue Engineering

Contact Information

RoosterBio, Inc.
5295 Westview Drive, Suite 275
Frederick, MD 21703
Customer Service: +1 240-831-4914
Headquarters: +1 301-200-5366
Email: info@roosterbio.com

Share

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn

Footer Navigation

  • Our Technology
  • Services
  • About Us
  • News & Events
  • Contact Us
  • Login
  • Products
    • Human Primary Cells
    • Cell & Exosome Media
    • Human Exosomes / Extracellular Vesicles
    • Genetic Engineering Tools
    • Cell & Media Kits
    • cGMP CliniControl™ Products
  • Knowledge Center
    • Resources
    • Blog Articles
    • Publications
    • Videos & Webinars

Copyright © 2026 RoosterBio, Inc. All Rights Reserved / Privacy Policy / Website design by Celerate

  • Share on Facebook
  • Tweet
  • Share on LinkedIn
  • Email